Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.

Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Brümmendorf TH, Khoury HJ.

Haematologica. 2018 Aug;103(8):1298-1307. doi: 10.3324/haematol.2017.171249. Epub 2018 May 17.

2.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH.

J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1.

3.

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.

Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, Talpaz M, Matczak E, Barry E, Leip E, Brümmendorf TH, Khoury HJ.

Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):684-695.e6. doi: 10.1016/j.clml.2017.06.001. Epub 2017 Jun 17.

4.

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.

Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, Matczak E, Leip E, Noonan K, Brümmendorf TH, Gambacorti-Passerini C.

Am J Hematol. 2016 Dec;91(12):1206-1214. doi: 10.1002/ajh.24536. Epub 2016 Sep 15.

5.

Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.

Cortes JE, Jean Khoury H, Kantarjian H, Brümmendorf TH, Mauro MJ, Matczak E, Pavlov D, Aguiar JM, Fly KD, Dimitrov S, Leip E, Shapiro M, Lipton JH, Durand JB, Gambacorti-Passerini C.

Am J Hematol. 2016 Jun;91(6):606-16. doi: 10.1002/ajh.24360. Epub 2016 Apr 13.

6.

Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.

Brümmendorf TH, Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Schafhausen P, Conlan MG, Shapiro M, Turnbull K, Leip E, Gambacorti-Passerini C, Lipton JH.

Br J Haematol. 2016 Jan;172(1):97-110. doi: 10.1111/bjh.13801. Epub 2015 Nov 4.

7.

Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.

Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brümmendorf TH, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes JE.

Am J Hematol. 2015 Sep;90(9):755-68. doi: 10.1002/ajh.24034. Epub 2015 Jun 1.

8.

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.

Isakoff SJ, Wang D, Campone M, Calles A, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Calvo E.

Br J Cancer. 2014 Nov 25;111(11):2058-66. doi: 10.1038/bjc.2014.508. Epub 2014 Oct 7.

9.

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE.

Am J Hematol. 2014 Jul;89(7):732-42. doi: 10.1002/ajh.23728. Epub 2014 Apr 28.

10.

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I.

Oncologist. 2014 Apr;19(4):348-9. doi: 10.1634/theoncologist.2014-0021. Epub 2014 Mar 27.

11.

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I.

Oncologist. 2014 Apr;19(4):346-7. doi: 10.1634/theoncologist.2014-0022. Epub 2014 Mar 27.

12.

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brümmendorf TH, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C.

Blood. 2014 Feb 27;123(9):1309-18. doi: 10.1182/blood-2013-07-513937. Epub 2013 Dec 17. Erratum in: Blood. 2014 Aug 7;124(6):981.

13.

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brümmendorf TH.

Blood. 2012 Apr 12;119(15):3403-12. doi: 10.1182/blood-2011-11-390120. Epub 2012 Feb 27.

14.

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA.

Clin Cancer Res. 2012 Feb 15;18(4):1092-100. doi: 10.1158/1078-0432.CCR-11-2378. Epub 2011 Dec 16.

15.

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C.

Blood. 2011 Oct 27;118(17):4567-76. doi: 10.1182/blood-2011-05-355594. Epub 2011 Aug 24. Erratum in: Blood. 2013 Oct 3;122(14):2524.

16.

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E, Fumoleau P, Ward R, Bardy-Bouxin N, Leip E, Turnbull K, Zacharchuk C, Epstein RJ.

Ann Oncol. 2012 Mar;23(3):610-7. doi: 10.1093/annonc/mdr261. Epub 2011 Jun 23.

PMID:
21700731
17.

Treatment of unruptured intracranial aneurysms: a nationwide assessment of effectiveness.

Higashida RT, Lahue BJ, Torbey MT, Hopkins LN, Leip E, Hanley DF.

AJNR Am J Neuroradiol. 2007 Jan;28(1):146-51.

18.

Obstructive sleep apnea and plasma natriuretic peptide levels in a community-based sample.

Patwardhan AA, Larson MG, Levy D, Benjamin EJ, Leip EP, Keyes MJ, Wang TJ, Gottlieb DJ, Vasan RS.

Sleep. 2006 Oct;29(10):1301-6.

PMID:
17068983
19.

Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample.

Fox CS, Larson MG, Hwang SJ, Leip EP, Rifai N, Levy D, Benjamin EJ, Murabito JM, Meigs JB, Vasan RS.

Kidney Int. 2006 Jun;69(11):2064-9.

20.

Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age.

Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D.

Circulation. 2006 Feb 14;113(6):791-8. Epub 2006 Feb 6.

PMID:
16461820
21.

Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study.

Fox CS, Larson MG, Vasan RS, Guo CY, Parise H, Levy D, Leip EP, O'donnell CJ, D'Agostino RB Sr, Benjamin EJ.

J Am Soc Nephrol. 2006 Feb;17(2):521-7. Epub 2005 Dec 28.

22.

Glycemic status and development of kidney disease: the Framingham Heart Study.

Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D.

Diabetes Care. 2005 Oct;28(10):2436-40.

PMID:
16186276
23.

Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study.

Franklin SS, Pio JR, Wong ND, Larson MG, Leip EP, Vasan RS, Levy D.

Circulation. 2005 Mar 8;111(9):1121-7. Epub 2005 Feb 21.

PMID:
15723980
24.

Novel approach to examining first cardiovascular events after hypertension onset.

Lloyd-Jones DM, Leip EP, Larson MG, Vasan RS, Levy D.

Hypertension. 2005 Jan;45(1):39-45. Epub 2004 Nov 15.

PMID:
15545512
25.

Usefulness of exercise testing in the prediction of coronary disease risk among asymptomatic persons as a function of the Framingham risk score.

Balady GJ, Larson MG, Vasan RS, Leip EP, O'Donnell CJ, Levy D.

Circulation. 2004 Oct 5;110(14):1920-5. Epub 2004 Sep 27.

PMID:
15451778
26.

Genomewide linkage analysis to serum creatinine, GFR, and creatinine clearance in a community-based population: the Framingham Heart Study.

Fox CS, Yang Q, Cupples LA, Guo CY, Larson MG, Leip EP, Wilson PW, Levy D.

J Am Soc Nephrol. 2004 Sep;15(9):2457-61.

27.

Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.

Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ.

Circulation. 2004 Aug 31;110(9):1042-6. Epub 2004 Aug 16.

PMID:
15313941
28.

Framingham risk score and prediction of lifetime risk for coronary heart disease.

Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D'Agostino RB, Levy D.

Am J Cardiol. 2004 Jul 1;94(1):20-4.

PMID:
15219502
29.

Predictors of new-onset kidney disease in a community-based population.

Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D.

JAMA. 2004 Feb 18;291(7):844-50.

PMID:
14970063
30.

Plasma natriuretic peptide levels and the risk of cardiovascular events and death.

Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS.

N Engl J Med. 2004 Feb 12;350(7):655-63.

31.

Impact of obesity on plasma natriuretic peptide levels.

Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS.

Circulation. 2004 Feb 10;109(5):594-600.

PMID:
14769680
32.

Lifetime risk of coronary heart disease by cholesterol levels at selected ages.

Lloyd-Jones DM, Wilson PW, Larson MG, Leip E, Beiser A, D'Agostino RB, Cleeman JI, Levy D.

Arch Intern Med. 2003 Sep 8;163(16):1966-72.

PMID:
12963571
33.

Heritability and genetic linkage of plasma natriuretic peptide levels.

Wang TJ, Larson MG, Levy D, Benjamin EJ, Corey D, Leip EP, Vasan RS.

Circulation. 2003 Jul 8;108(1):13-6. Epub 2003 Jun 23.

PMID:
12821537
34.

Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.

Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, Kannel WB, Benjamin EJ.

Circulation. 2003 Jun 17;107(23):2920-5. Epub 2003 May 27.

PMID:
12771006
35.

Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study.

Freitag MH, Larson MG, Levy D, Benjamin EJ, Wang TJ, Leip EP, Wilson PW, Vasan RS; Framingham Heart Study.

Hypertension. 2003 Apr;41(4):978-83. Epub 2003 Mar 3.

PMID:
12623868
36.

Lifetime risk for developing congestive heart failure: the Framingham Heart Study.

Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D; Framingham Heart Study.

Circulation. 2002 Dec 10;106(24):3068-72.

PMID:
12473553
37.

Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.

Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D.

JAMA. 2002 Sep 11;288(10):1252-9.

PMID:
12215132
38.

Impact of age and sex on plasma natriuretic peptide levels in healthy adults.

Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, Sutherland P, Omland T, Vasan RS.

Am J Cardiol. 2002 Aug 1;90(3):254-8.

PMID:
12127613
39.

Serum potassium and risk of cardiovascular disease: the Framingham heart study.

Walsh CR, Larson MG, Leip EP, Vasan RS, Levy D.

Arch Intern Med. 2002 May 13;162(9):1007-12.

PMID:
11996610
40.

Impact of high-normal blood pressure on the risk of cardiovascular disease.

Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D.

N Engl J Med. 2001 Nov 1;345(18):1291-7.

41.

Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study.

Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D.

Lancet. 2001 Nov 17;358(9294):1682-6.

PMID:
11728544
42.

Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study.

Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D.

Circulation. 2001 Mar 6;103(9):1245-9.

PMID:
11238268

Supplemental Content

Support Center